U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07401823) titled 'Open-Label Extension Study to Pioneer Study 6058-SCD-101' on Jan. 28.
Brief Summary: This is an open-label study to evaluate the safety and tolerability of long-term treatment with pociredir without a comparator in participants with SCD who have previously been treated and shown benefit with pociredir in feeder study 6058-SCD-101 (NCT05169580). Participants in this study will receive once daily doses of pociredir for up to 48 months.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Sickle Cell Disease
Intervention:
DRUG: Pociredir
Pociredir Oral Capsules will be administered
Recruitment Status: NOT_YET_REC...